Latest News and Press Releases
Want to stay updated on the latest news?
-
CAMBRIDGE, Mass., March 03, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at...
-
CAMBRIDGE, Mass., March 02, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today reported financial and operating results for the fourth quarter and year ended December 31,...
-
CAMBRIDGE, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product...
-
CAMBRIDGE, Mass., Feb. 23, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product...
-
CAMBRIDGE, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at...
-
CoLucid Pharmaceuticals and IMS Health Publish White Paper to Address Migraine Market Misperceptions
CAMBRIDGE, MA, Jan. 05, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...
-
CAMBRIDGE, Mass., Dec. 8, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...
-
CAMBRIDGE, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that over 50% of the migraine patients needed to complete the Company's SAMURAI trial,...
-
CAMBRIDGE, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at the...
-
CAMBRIDGE, Mass., Nov. 10, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today reported financial and operating results for the third quarter ended September 30,...